Ελληνικά
Endometrial cancer is the most commonly diagnosed gynaecological cancer and is the 4th most common cancer in UK women. Endometrial cancer rates have increased substantially; in the UK over 9,000 cases occur annually and rates have increased by over 50% over the past 20 years. Factors associated with prolonged oestrogen exposure are thought to be driving this including the dramatic increase in obesity rates and shifts in reproductive trends, e.g. delaying childbirth until later in life. There is no routine screening for endometrial cancer but endometrial hyperplasia, a recognised precursor, offers an opportunity for prevention, but little is known about its natural history and associated outcomes. Removal of the uterus (hysterectomy) is the primary treatment for endometrial cancer and some types of endometrial hyperplasia but there is a need to evaluate the long-term benefits and risks of fertility-sparing therapies, considering the alarming increases in endometrial cancer in premenopausal women. This research will answer three primary research questions: 1. Which women are most at risk of progression from endometrial hyperplasia to cancer? 2. What is the impact of non-surgical, fertility-sparing therapies on future cancer risk and reproductive outcomes in endometrial hyperplasia patients? 3. What are the international trends in surgical and non-surgical treatments of endometrial cancer and how do these impact upon survival outcomes? A pilot endometrial hyperplasia register, located within the Northern Ireland Cancer Registry (NICR), will be utilised and expanded upon to make it one of the world's largest endometrial hyperplasia registers. The register will be linked to NICR records to determine temporal trends in endometrial hyperplasia incidence and progression to endometrial cancer. Medical note reviews will provide details on patient and clinico-pathological factors while additional novel data linkages to drug dispensing and maternity records in Northern Ireland (NI) will be conducted to evaluate, for the first time, population patterns of low-cost progestogen therapies (delivered orally or, more recently via intrauterine devices) in endometrial hyperplasia patients and their long-term impact on clinical outcomes such as hysterectomy, live births and progression to cancer. Using population-based linked data sources, accessed from established research links, European trends in the use of surgical and non-surgical treatments for endometrial cancer will be determined for the first time according to geography and healthcare systems. Pooled analyses of large endometrial cancer cohorts from the UK, Belgium and the Netherlands will be conducted to evaluate survival outcomes according to non-surgical, progestogen-based therapies. Future research will explore the development of patient decision aid tools to enable better informed joint treatment decision making. The involvement of patients and clinicians throughout will ensure that the research is clinically relevant. This research programme will generate robust population-level evidence to inform diagnostic, treatment and surveillance strategies for women with endometrial hyperplasia and endometrial cancer and will ultimately lead to better informed clinical decision-making between women and their health care professionals.
